<div id="readability-page-1"><p>Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $21.30, but opened at $22.19. Arcus Biosciences shares last traded at $22.4330, with a volume of 1,292,918 shares traded.</p><div><p><span></span><span>Get <strong>Arcus Biosciences</strong> alerts:</span></p></div><h2>Analysts Set New Price Targets</h2><ul><li>From laggards to leaders: Small caps on the rise</li></ul><p>RCUS has been the subject of a number of recent research reports. Truist Financial  set a $30.00 price objective on shares of Arcus Biosciences in a research note on Friday, December 12th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Wells Fargo &amp; Company raised their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, October 20th. Morgan Stanley  reiterated an &#34;equal weight&#34; rating and issued a $20.00 target price (down from $23.00) on shares of Arcus Biosciences in a report on Thursday, January 8th. Finally, The Goldman Sachs Group upgraded shares of Arcus Biosciences from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and raised their price target for the company from $16.00 to $28.00 in a report on Monday. Eight equities research analysts have rated the stock with a Buy rating, two have assigned  a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat.com, Arcus Biosciences currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $30.00.</p><p><b>Get Our Latest Stock Analysis on RCUS</b></p><h2>Arcus Biosciences Stock Up 4.8%</h2><ul><li>MarketBeat Week in Review – 7/10 - 7/14</li></ul><p>The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -6.49 and a beta of 0.77. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The business has a fifty day moving average price of $22.62 and a two-hundred day moving average price of $15.72. </p><p>Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating analysts' consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The firm had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. During the same quarter in the prior year, the firm earned ($1.00) earnings per share. Arcus Biosciences's revenue for the quarter was down 45.8% on a year-over-year basis.  On average, equities analysts expect that  Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year. </p><h2>Insider Buying and Selling</h2><ul><li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li></ul><p>In related news, CEO Terry J. Rosen sold 28,947 shares of the business's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total transaction of $633,360.36. Following the completion of the transaction, the chief executive officer directly owned 2,220,553 shares in the company, valued at $48,585,699.64. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jennifer Jarrett sold 11,225 shares of the company's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total transaction of $245,603.00. Following the completion of the sale, the chief operating officer directly owned 203,007 shares in the company, valued at approximately $4,441,793.16. The trade was a 5.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 422,060 shares of company stock valued at $9,286,202 over the last 90 days. Insiders own  9.60% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in shares of  Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company's stock worth $37,000 after buying an additional 1,021 shares during the last quarter.  SBI Securities Co. Ltd. raised its stake in  Arcus Biosciences by 13,547.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company's stock worth $39,000 after acquiring an additional 2,845 shares in the last quarter.  Abich Financial Wealth Management LLC purchased a new stake in  Arcus Biosciences in the third quarter valued at $69,000.  CWM LLC lifted its position in  Arcus Biosciences by 233.6% in the second quarter. CWM LLC now owns 5,441 shares of the company's stock valued at $44,000 after acquiring an additional 3,810 shares during the last quarter.  Finally, Ameritas Investment Partners Inc. boosted its stake in  Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company's stock valued at $57,000 after acquiring an additional 1,796 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Arcus Biosciences Company Profile</h2> (Get Free Report)<p>Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company's research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.  </p><p>The company's lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Arcus Biosciences</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2><p>Before you consider Arcus Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RCUS

<p>Arcus Biosciences (NYSE:RCUS) shares gapped up from $21.30 to $22.19 before trading, closing at $22.43 with a volume of 1,292,918 shares. Analysts have set varied price targets, with Truist Financial at $30.00 and Wells Fargo at $29.00. The company reported a quarterly revenue of $26 million, beating estimates, but had a negative EPS of ($1.27). Insider selling occurred, with CEO Terry J. Rosen selling shares valued at $633,360. Institutional investors have also increased their stakes in the company recently.</p>

Arcus Biosciences (NYSE:RCUS) Shares Gap Up - Here's What Happened